v3.25.4
Collaborative and Other Relationships - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 194 Months Ended
May 11, 2025
Nov. 30, 2009
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2025
License agreements              
Contract dispute settlement       $ 242,251 $ 0 $ 0  
Revenues       5,141,242 4,241,217 3,695,649  
United States              
License agreements              
Revenues       4,799,941 3,974,567 3,514,873  
JAKAFI              
License agreements              
Revenues       3,092,515 2,792,107 2,593,732  
Novartis | Development Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             $ 157,000
Novartis | Development Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement   $ 174,000          
Novartis | Regulatory Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             345,000
Novartis | Regulatory Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement   495,000          
Novartis | Commercialization Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             200,000
Novartis | Commercialization Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement   500,000          
Novartis | GVHD | Development and Regulatory Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement   $ 75,000          
Novartis | JAKAFI              
License agreements              
Royalties payable     $ 537,100        
Litigation settlement, amount awarded to other party $ 280,000            
Royalty rate payable, percent reduction (as a percent) 50.00%            
Decrease in royalties payable     $ 14,900        
Contract dispute settlement       242,200      
Novartis | JAKAFI | United States              
License agreements              
Royalties payable       20,300 507,400   $ 20,300
Revenues       88,100 131,800 122,100  
Novartis | JAKAVI              
License agreements              
Revenues       $ 457,700 418,800 367,600  
Novartis | JAKAVI | Maximum              
License agreements              
Royalty payments on future global net sales (as percent)       14.00%      
Novartis | JAKAVI | Minimum              
License agreements              
Royalty payments on future global net sales (as percent)       12.00%      
Novartis | TABRECTA              
License agreements              
Revenues       $ 26,700 $ 22,700 $ 17,800